Harmony Biosciences to Submit NDA for Narcolepsy Treatment Following Trial Results

MT Newswires Live

11/24

Harmony Biosciences (HRMY) said Monday that it expects to submit a New Drug Application to the US Food and Drug Administration in early 2026 for gastro-resistant Wakix (pitolisant GR) to treat narcolepsy.

The pharmaceutical company said the evaluation is based on a pivotal bioequivalence study, which it said confirmed that the 17.8mg dose of the gastro-resistant drug is bioequivalent to existing 17.8mg Wakix tablets.

Harmony also reported that there were no new safety or tolerability issues, and that topline data from the dosing optimization study of Wakix showed that 100% of patients successfully initiated treatment at the therapeutic dose of 17.8mg, which eliminated the need for dose titration.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2585460695"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2585460695\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2585460695?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-24 22:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585460695","market":"sh","top_or_hot":-1,"title":"Harmony Biosciences to Submit NDA for Narcolepsy Treatment Following Trial Results","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/HRMY\">Harmony Biosciences</a> (HRMY) said Monday that it expects to submit a New Drug Application to the US Food and Drug Administration in early 2026 for gastro-resistant Wakix (pitolisant GR) to treat narcolepsy.</p><p>The pharmaceutical company said the evaluation is based on a pivotal bioequivalence study, which it said confirmed that the 17.8mg dose of the gastro-resistant drug is bioequivalent to existing 17.8mg Wakix tablets.</p><p>Harmony also reported that there were no new safety or tolerability issues, and that topline data from the dosing optimization study of Wakix showed that 100% of patients successfully initiated treatment at the therapeutic dose of 17.8mg, which eliminated the need for dose titration.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harmony Biosciences to Submit NDA for Narcolepsy Treatment Following Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarmony Biosciences to Submit NDA for Narcolepsy Treatment Following Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-24 22:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/HRMY\">Harmony Biosciences</a> (HRMY) said Monday that it expects to submit a New Drug Application to the US Food and Drug Administration in early 2026 for gastro-resistant Wakix (pitolisant GR) to treat narcolepsy.</p><p>The pharmaceutical company said the evaluation is based on a pivotal bioequivalence study, which it said confirmed that the 17.8mg dose of the gastro-resistant drug is bioequivalent to existing 17.8mg Wakix tablets.</p><p>Harmony also reported that there were no new safety or tolerability issues, and that topline data from the dosing optimization study of Wakix showed that 100% of patients successfully initiated treatment at the therapeutic dose of 17.8mg, which eliminated the need for dose titration.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HRMY","symbol_name":"Harmony Biosciences Holdings, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2585460695","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585460695","pubTimestamp":1763993303,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Harmony Biosciences  said Monday that it expects to submit a New Drug Application to the US Food and Drug Administration in early 2026 for gastro-resistant Wakix  to treat narcolepsy.The pharmaceutical company said the evaluation is based on a pivotal bioequivalence study, which it said confirmed that the 17.8mg dose of the gastro-resistant drug is bioequivalent to existing 17.8mg Wakix tablets.Harmony also reported that there were no new safety or tolerability issues, and that topline data from the dosing optimization study of Wakix showed that 100% of patients successfully initiated treatment at the therapeutic dose of 17.8mg, which eliminated the need for dose titration.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HRMY":"Harmony Biosciences Holdings, Inc.","BK4007":"制药"},"translate_title":"Harmony Biosciences将根据试验结果提交治疗发作性睡病的NDA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HRMY":1},"content_text":"Harmony Biosciences (HRMY) said Monday that it expects to submit a New Drug Application to the US Food and Drug Administration in early 2026 for gastro-resistant Wakix (pitolisant GR) to treat narcolepsy.The pharmaceutical company said the evaluation is based on a pivotal bioequivalence study, which it said confirmed that the 17.8mg dose of the gastro-resistant drug is bioequivalent to existing 17.8mg Wakix tablets.Harmony also reported that there were no new safety or tolerability issues, and that topline data from the dosing optimization study of Wakix showed that 100% of patients successfully initiated treatment at the therapeutic dose of 17.8mg, which eliminated the need for dose titration.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}